Ezbon International Ltd's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Dec 5, 2022
- Accession no.
- 0001062993-22-023333
- Filed
- Dec 5, 2022, 4:36 PM ET
- Trade date
- Dec 1, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $71.2M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ezbon International LtdCIK 0001869027 | Other: Former 10% owner |
| Blue Horizon Enterprise LtdCIK 0001869057 | Other: Former 10% owner |
| Montrago Trustees LtdCIK 0001869331 | Other: Former 10% owner |
| Skorpios TrustCIK 0001869333 | Other: Former 10% owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | SSaleDisposed | −1,636,000 | $43.50 | −$71,166,000 | 3,271,829 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.